UK MHRA Launches Women's Health Programme on 16 November: Pregnant Women in Just 1.1% of 4,616 Trial Applications

The UK Medicines and Healthcare products Regulatory Agency (MHRA) announced on 16 November the launch of its Women's Health Programme, aimed at tackling evidence gaps on medicines and medical devices, including how their risks and benefits may differ for women.
An MHRA analysis of all 4,616 UK clinical trial applications submitted between 2019 and 2023 found pregnant women represented in just 1.1% of trials and breastfeeding women in 0.6%. The agency said women make up 51% of the population but have historically been underrepresented in clinical research, limiting evidence during pregnancy and across reproductive health.
Women's Health Minister Baroness Gillian Merron said women's health had been overlooked for too long and that the programme, together with the renewed Women's Health Strategy for England, would mean better evidence and better treatments. MHRA Chief Executive Lawrence Tallon said closing the gaps in understanding how risks and benefits differ for women was both a challenge and a huge opportunity.
The announcement was made at the inaugural DIA-MHRA Global Summit in London on 16-17 November 2026, part of London Life Sciences Week. The MHRA will host a webinar on 9 December introducing the programme. The UK FemTech sector already has an annual turnover of nearly 300 million pounds.
Published by GSM · USA (original Chinese edition)
Photo: Wikimedia Commons, File:10 South Colonnade and Canary Wharf DLR (south side).jpg, CC BY-SA

